Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma
      QxMD      Google Scholar   
Citation:
Cancer vol 113 (3) 508-514
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, CA112904, CA97274, CA-35090, U10 CA060276, CA-35195, U10 CA037404, U10 CA035448, U10 CA063848, U10 CA035195, CA-25224, CA-37403, CS-35431, CA-60276, CA-35113, U10 CA035101, U10 CA035113, P30 CA015083, CA-63848, U10 CA035415, CA-63826, R21 CA112904, CA-35415, P50 CA097274, CA-35448, CA-35101, U10 CA025224, U10 CA035090, CA-15083, CA-35267, N01 CA015083  
Corr. Author:
 
Authors:
                         
Primary Study
N0186
Secondary Studies:
Phases:
2
Keywords:
mantle cell lymphoma, temsirolimus, CCI-779, rapamycin, mammalian target of rapamycin kinase